Comparable studies in mice showed PTEN overexpression did not alter NK cell development or NK cell-activating and inhibitory receptor expression yet, as in humans, did decrease expression of downstream NK activation targets MAPK and AKT during early cytolysis of tumor target cells. Confocal microscopy revealed that PTEN overexpression disrupts the NK cell's ability to organize immunological synapse components including decreases in actin accumulation, polarization of the microtubule organizing center, and the convergence of cytolytic granules. In summary, our data suggest that PTEN normally works to limit the NK cell's PI3K/AKT and MAPK pathway activation and the consequent mobilization of cytolytic mediators toward the target cell and suggest that PTEN is among the active regulatory components prior to human NK cells transitioning from the noncytolytic CD56 bright NK cell to the cytolytic CD56 dim NK cells.
H uman NK cells are CD56
+ CD3 2 large granular lymphocytes of the innate immune system, which are characterized by the ability to both directly kill and initiate an immune response to virally infected or malignantly transformed cells (1) . In human blood, NK cells can be divided into two developmentally and functionally distinct subsets based upon cell-surface expression of CD56. In contrast to the more mature CD56 dim NK cell, the less mature CD56 bright NK cell is unable to efficiently kill malignant cells at rest (2) . The molecular mechanisms underlying this difference are incompletely defined.
In order for NK cells to carry out an effective yet controlled response, NK cell activation is mediated by a dynamic integration of signaling through activating and inhibitory receptors on the NK cell surface, which, in turn, are regulated by kinases and phosphatases, respectively. Further, in the case of cytotoxicity mediated by the release of lytic granules, the NK cell must integrate these signals to execute the proper directional secretion of the granules onto the target cell (3) . Previous reports have demonstrated the importance of the PI3K/AKT and MAPK pathways for regulating NK cell cytolytic activity (4) (5) (6) (7) . Additionally, in human NK cells, the 59-lipid phosphatase SHIP-1 is a negative regulator of PI3K/AKT and MAPK, and high SHIP-1 expression correlates with decreased NK cell natural cytotoxicity and IFN-g production (8) .
The 39-lipid phosphatase called phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a critical tumor sup-pressor for which mutations and/or deletions occur in and are associated with a wide variety of cancers (9) . Additionally, inherited mutations of PTEN encompass a clinical spectrum of disorders referred to as PTEN hamartoma tumor syndromes, including Cowden syndrome, Bannayan-Riley-Ruvalcalba syndrome, Proteus syndrome, and Proteus-like syndrome (10) .
A major mechanism of PTEN-mediated tumor suppression has been attributed to its function as a lipid phosphatase inhibitor of the PI3K/AKT pathway; however, PTEN has proven to be a complex regulator of cellular homeostasis with both lipid phosphatasedependent and -independent roles in proliferation, senescence, motility, and chromosomal stability (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . Recently, PTEN has also emerged as an important regulator of immune function. Loss of Pten in T cells can lead to variable consequences ranging from a lethal autoimmunity to enhancement or deficiency in tumor immunity depending upon the developmental timing and the specific T cell subset in which PTEN is deleted (21) (22) (23) (24) (25) (26) . To our knowledge, a role for PTEN in regulating NK cell immune function has not been investigated. In this report, we provide an investigation of PTEN expression and function in human and mouse NK cells and assess its role in the regulation of cytotoxicity against leukemic target cells.
Materials and Methods

NK cell preparations
Human and murine NK cells were isolated and cultured as described (27, 28) . All human work was approved by the Institutional Review Board of The Ohio State University. All animal work was approved by The Ohio State University Animal Care and Use Committee.
Immunoblot
Immunoblots were run as described (29) . Abs used were: rabbit monoclonal anti-PTEN, anti-phospho-AKT
Ser473
, anti-phospho-ERK Thr202/Tyr204 (Cell Signaling Technology), and mouse anti-GRB2 Ab (BD Pharmingen). Densitometry was determined using ImageJ software (National Institutes of Health). The area gated in compared samples was determined by the largest visible band in each developed film. Relative protein of interest levels were then normalized to loading controls, and ratios were calculated as the difference between these values.
Real-time PCR
Total RNAs were extracted from 20,000-40,000 cells/sample using RNeasy Mini Kit (catalog number 74106; Qiagen). First-strand cDNAs were synthesized using SuperScript VILO Master Mix (catalog number 11755250; Invitrogen). Data were analyzed using the comparative d-d threshold cycle method and normalized to 18sRNA for loading controls. Results (mean 6 SD of triplicate wells) are represented as fold changes of expression levels.
Confocal microscopy
Normal donor NK cells were enriched with RosetteSep (StemCell Technologies), incubated on anti-CD18 and anti-CD56 Ab-coated glass slides at 37˚C for 30 min, and then permeabilized and stained intracellularly as described (30) . F-actin was detected with Phalloidin Alexa Fluor 568 (Life Technologies) and perforin with anti-perforin FITC (BD Pharmingen). PTEN was detected by anti-PTEN mAb (Thermo Scientific) followed by Alexa Fluor 647 goat anti-mouse Ab (Life Technology). Coverslips were mounted with Vectashield (Vector Laboratories).
Mice
Super-PTEN transgenic mice (C57BL/6J) have been described (31) .
Plasmids
PTEN cDNAs were cloned into a pCDH-EF1-MCS-T2A-copGFP vector (System Biosciences). PTEN cDNA was cloned out of a pCMV6-XL5 vector (Origene). PTEN cDNA with a mutation in the lipid phosphatase catalytic site (G129E) was cloned out of a published vector [Addgene plasmid 30377 (32)]. A short-hairpin sequence targeting PTEN was cloned into PSIH1-H1-copGFP vector (System Biosciences).
Cells lines
The human IL-2-dependent NK cell line NK-92 (ATCC CRL-2407; American Type Culture Collection) was maintained in culture in RPMI 1640 medium supplemented with 20% heat-inactivated FBS (Invitrogen), 2 mM L-glutamine, and 150 IU/ml recombinant human IL-2 (HoffmanLaRoche). The YAC-1 mouse T-lymphoma cell line and human erythroleukemia cell line K562 (American Type Culture Collection) were maintained in RPMI 1640 supplemented with 10% heat-inactivated FBS and 2 mM L-glutamine. The amphotropic-packaging cell line 293T (American Type Culture Collection) was maintained in culture in DMEM/10% FBS medium and grown for 16-18 h to 80% confluence prior to transfection by calcium phosphate-DNA precipitation (Profection system; Promega).
Lentiviral infections
293T packaging cells were seeded onto a 15-cm dish (catalog number 430599; Corning) at 5 to 6 3 10 6 /40 ml/dish. Cells reaching 80-90% confluence 40-48 h later were used for cotransfection. Media were switched to 40 ml fresh D10F with chloroquine (25 mM at final) before cotransfection to assemble lentiviruses. Three plasmids were used to prepare DNA precipitates. These included the control or experimental construct (100 mg) and the packaging plasmids VSVG (50 mg) and deltaR9 (150 mg). The plasmids were diluted with 1x TE (pH 8) to a final volume of 1.0125 ml, and then 112.5 ml 2 M CaCl 2 was added and mixed. An equal volume of 1.125 ml 2x HBS buffer (50 mM HEPES, 280 mM NaCI, 12 mM dextrose, 10 mM KCI, and 1.5 mM Na 2 PO 4 [pH 7.05]) was added to the mixture. The whole mixture was quickly vortexed for 30-45 s and then added to the top of the media immediately without disturbing the single cell layer. Cells were cultured in a 37˚C incubator supplied with 3% CO 2 . After overnight media was removed and 40 ml fresh D10F was added, cells were cultured in a 37˚C incubator with 5% CO 2 , and sodium butyrate was added at a final concentration of 1 mM. Viral supernatants were harvested twice at 24 and 48 h after adding sodium butyrate, respectively. The 24-and 48-h supernatants were merged and passed through 0.45-um size filter after spinning at 2000 rpm for 5 min. Filtered viral supernatants were centrifuged at 16,500 rpm for 90 min at 4˚C. After centrifugation, supernatants were removed, and fresh supernatants containing virus were added to the same tubes containing virus pellets from the previous round. Three to four rounds of successive ultracentrifugation were performed and resuspended in 900-1000 ml 1x PBS overnight at 4˚C and transferred to 280˚C until use. For primary experiments, human primary NK cells were enriched from leukopacks using the RosetteSep kit (catalog number 15065; StemCell Technologies) following the manufacture's protocol with 60-70% purity. NK subsets were sorted from enriched NK cells using the FACSAria II sorter (BD Biosciences) with a typical purity .98 to 99% and a total number of 1.0-1.6 3 10 6 cells/ donor were obtained after sorting. Sorted bright NK cells were cultured at 0.5-0.8 3 10 6 cells/200 ml/well in 96-well plate (round bottom) with RPMI 1640 containing 10% FBS and 5% glutamate (R10F), together with 450 U/ml IL-2. After overnight culture, 180 ml media was removed following spinning of the plate at 2000 rpm for 5 min at room temperature, and 100 ml concentrated viruses were added to each well, together with an equal volume of RPMI 1640 containing 20% FBS, 900 U/ml IL-2, and 16 mg/ml polybrene. The cells were mixed well with viruses and cultured for 1 h in a 37˚C incubator supplied with 5% CO 2 , followed by spinning in a microcarrier bucket at 2000 rpm for 2 h at 20-25˚C. This infection procedure of 1-h culture plus 2-h spin was repeated three times. Before each round of adding new viruses, all supernatants were collected and transferred to a six-well plate. After the last spin, cells including all supernatants were transferred to a six-well plate and merged with previous supernatants. Fresh media (R10F) containing 450 U/ml IL-2 was then added to a final of volume of 6 ml/well. A total multiplicity of infection of 4-10 was used for transduction. 
NK cell activation assays
For assessment of NK-92 activation during cytotoxicity with K562 leukemic cells, NK-92 cells were starved from IL-2 for 2 h on ice, then mixed with paraformaldehyde-fixed K562 cells at a 5:1 ratio, and stimulated for the indicated times as described (7) . For mice, primary mouse NK cells were expanded in IL-2 for $8 d, starved from IL-2 for 2 h on ice, then mixed with paraformaldehyde-fixed YAC-1 lymphoma cells at a 5:1 ratio, and stimulated for the indicated times.
Cytotoxicity assays
For mice, YAC-1 cells were combined with primary mouse NK cells in a standard cytotoxicity assay (7) following NK cell culture in 900 IU/ml IL-2 for 8 d. For humans, K562 leukemic cells were used as targets in a 4-h [ 51 Cr] release assay (7) with empty vector, Over-PTEN, Over-PTEN-G129E, and short hairpin RNA-targeting PTEN (shPTEN)-infected NK-92 and/or primary NK cells that were cultured in 150 IU/ml IL-2.
Immune conjugates assessed by confocal microscopy Conjugate formation, fixation, and permeabilization were performed as described (33) followed sequentially by: 1) staining with PTEN as described above; or 2) blocking with 10 mg/ml mouse IgG; anti-a tubulinbiotynlated Ab (1:50; Invitrogen); streptavidin-Pacific Blue (1:50; Invitrogen); anti-perforin FITC Ab (1:3; BD Biosciences); and Phalloidin AF-568 (1:100; Invitrogen).
For analysis, a fixed-intensity threshold was used to detect perforin or a-tubulin staining above the background, and the a-tubulin-defined microtubule organizing center (MTOC) was located as described (33) . MTOC polarization, granule convergence, and F-actin accumulation were measured as described (34) . Although there is spectral overlap between GFP and FITC, the images for Fig. 5 were generated using permeabilized and fixed cells. To avoid any residual GFP overlap with FITC, we employed single fluorophore controls (GFP-only and FITC-only) to identify a laser power and camera exposure time that adequately detected FITC while not detecting any GFP fluorescence above background.
Statistics
For donor cell data, we calculated ratios between CD56 bright NK and CD56 dim NK cells and performed a one-sample t test on log-transformed ratios for difference. For cytolytic activity data, we employed an ANOVA model with treatment and target ratio as effects and experiment as block factor. The t test was then used for testing treatment differences. Multiplicity was adjusted by Holm's method for significance (35) . (Fig. 1A, 1B , average increase 5.29; n = 4, p , 0.02; range 2.4-9.4). We confirmed this using confocal microscopy, which showed that NK cells brightest for CD56 also expressed the highest levels of PTEN protein (Fig. 1C, 1D ; average 2.2-fold increase in mean Fig. 1E ; n = 3, p , 0.04).
Results
PTEN
fluorescence intensity 3 area; p , 0.0001). To determine whether PTEN is regulated at the translational level, we investigated the expression
PTEN expression negatively correlates with NK cell cytolytic activity
To determine the effect of PTEN expression on NK cell cytolytic activity, we infected the human NK cell line NK-92 with a lentiviral vector encoding either GFP (pCDH-EF1-MCS-T2A-copGFP [empty vector]) or GFP and PTEN (pCDH-EF1-MCS-T2A-copGFP-PTEN [Over-PTEN]) and confirmed PTEN protein overexpression by immunoblot (Fig. 2A) . Over-PTEN NK-92 cells showed a significantly decreased efficiency in cytotoxicity against the NK-sensitive leukemic cell line K562 ( Fig. 2B ; n = 3, p , 0.0001). To confirm these findings, we infected primary human NK cells isolated from healthy donors with either empty vector or Over-PTEN. We confirmed PTEN expression by immunoblot (Fig. 2C ). In agreement with our findings in the NK-92 cell line, primary NK cells overexpressing PTEN demonstrated a significant decrease in cytolytic activity against leukemic target cells ( Fig. 2D ; n = 3, p , 0.03). Given our observation that PTEN expression is higher in CD56 bright NK cells that have lower cytotoxic activity, we sought to determine if loss of PTEN would increase the cytolytic activity in this population. Therefore, we used a lentiviral vector encoding either GFP (PSIH1-H1-copGFP [empty vector]) or GFP and a short-hairpin RNA targeting PTEN (PSIH1-H1-copGFP-shPTEN [shPTEN]). We confirmed PTEN knock down by immunoblot (Fig. 2E) . Loss of PTEN protein led to a significant increase in NK cell cytolytic activity among the less mature CD56 bright NK cells ( Fig. 2F ; n = 3, p , 0.03), further supporting a role for PTEN in suppressing NK cell cytolytic activity in this subset.
Effect of PTEN overexpression on murine NK cell cytolytic activity and development
To determine whether PTEN regulates murine NK cell cytolytic activity, we isolated NKp46 + CD3 2 NK cells from Super-PTEN transgenic mice (31) . We confirmed overexpression of PTEN in Super-PTEN NK cells by immunoblot (Fig. 3A) we saw no significant change in the proportions of any of the aforementioned populations compared with WT mice, indicating that PTEN overexpression does not disrupt NK cell terminal development ( Fig. 3C ; n = 3, p = 0.980). In addition, there were no significant differences in the expression of NK1.1, 2B4, DX5, Ly49H, Ly49D, Ly49A, CD117, CD94, NKG2D, CD27, KLRG1, CD69, CD62L, NK2ACE, and CD16 (Fig. 3D) .
Effect of PTEN overexpression on activation of AKT and MAPK
The PI3K/AKT pathway is important for NK cell-mediated cytotoxicity (9), and PTEN regulates the PI3K/AKT pathway. Therefore, we sought to determine if downregulation of PI3K/ AKT might account for the decrease in cytolytic activity observed in PTEN-overexpressing NK cells (39) . To test this, we stimulated NK-92 cells overexpressing PTEN with fixed K562 target cells for 0, 1, 3, and 10 min and assessed activated AKT. NK-92 cells overexpressing PTEN cells showed a marked reduction in AKT activation during early cytolysis (Fig. 4A) . Similarly, Super-PTEN murine NK cells stimulated with Yac-1 target cells also showed a marked reduction in AKT (Fig. 4B ). An additional downstream target of PI3K is ERK (MAPK), which is a positive regulator of NK cell cytotoxicity (4, 5, 7) . Sustained ERK activation was significantly decreased in both human NK-92 cells overexpressing PTEN and Super-PTEN mouse NK cells compared with respective controls (Fig. 4A, 4B , respectively).
To determine if the negative regulation of NK cell cytolytic activity by PTEN was due to activity at PTEN's lipid phosphatase catalytic site, we generated an NK-92 cell line that overexpressed PTEN with a glycine to glutamate substitution in position 129 (Over-PTEN-G129E), a mutation known to disrupt PTEN's lipid phosphatase activity (Fig. 4C) (32) . This mutation led to a recovery of AKT and ERK activation levels upon stimulation with fixed K562 cells (Fig. 4D) , and rescued cytolytic activity to levels not significantly different from empty vector (Fig. 4E) .
Effect of PTEN loss on directed granule mobilization
To kill, the NK cell must polarize in response to target binding, and PI3K is crucial in generating directional polarization of NK cells, which in turn is important for E:T cell conjugation (3, 26) . We compared NK cell-target cell conjugates between NK-92 cells infected with empty vector and NK-92 cells overexpressing PTEN. NK-92 cells overexpressing PTEN showed decreased polarization of the MTOC (Fig. 5A, 5B ; n $ 15, p , 0.01) and decreased convergence of lytic granules to the microtubule organizing center (MTOC) (Fig. 5A, 5C ; n $ 15, p , 0.01). Additionally, NK-92 cells overexpressing PTEN showed significantly decreased F-actin at the immune synapse ( Fig. 5A, 5D ; n $ 15, p , 0.01). Taken together, these data indicate that NK-92 cells overexpressing PTEN have significantly decreased polarization, granule convergence, and F-actin accumulation at the immune synapse compared with NK-92 cells expressing empty vector, suggesting that PTEN does indeed participate in the directional polarization of NK cells following tumor cell conjugation.
Discussion
Certain lipid phosphatases have been shown to be key regulators of NK cell activity against malignant targets; however, the tumor suppressor and lipid phosphatase PTEN had yet to be investigated in NK cells (40) . In this report, we use a combination of human and murine studies to assess the role of PTEN in NK cell cytolytic function. We observed that PTEN is more highly expressed in resting noncytolytic CD56 bright NK cells than in resting cytolytic CD56 dim NK cells, and we therefore hypothesized that the level of PTEN expression in human NK cells could be important in the acquisition and maintenance of NK cell cytolytic function as occurs during NK cell development. Forced overexpression of PTEN reduced activation of the PI3K/AKT and MAPK pathways during conjugation with malignant targets in both human and mouse NK cells and consequently reduced cytolytic activity when compared with appropriate controls. The physiologic importance of PTEN was also demonstrated by PTEN knockdown experiments in the CD56 bright NK cell subset that showed that a decrease in PTEN protein expression led to an increase in cytolytic activity. The importance of PI3K/AKT and MAPK in the cytolytic pathway of lymphocytes has been reported (4-7) and was validated by our overexpression of PTEN with a point mutation that disabled its lipid phosphatase activity. This resulted in restoration of PI3K/ AKT activation and subsequently restored NK cell cytolytic function. We also observed a failure to polarize the MTOC and a significant decrease in granule convergence at the MTOC in NK cells with overexpression of PTEN. Thus, our data suggest that PTEN normally works to limit the NK cell's PI3K/AKT and MAPK pathway activation and the consequent mobilization of cytolytic mediators toward the target cell.
Developmentally, it now appears clear that human cytolytic CD56 dim NK cells differentiate from the less mature, noncytolytic CD56 bright NK cells (41) (42) (43) (44) (45) , and the current study shows that PTEN undergoes a .5-fold reduction in protein expression during this transition. Forced overexpression of PTEN in mice did not alter NK cell differentiation as determined by the quantity of immature and mature NK cell subsets and by the acquisition of NK cell activating and inhibitory receptors; however, it did prevent the phenotypically more mature NK cell subsets from acquiring optimal cytolytic activity. Thus, with a 5-fold greater expression in the CD56 bright NK cell subset, it is possible that PTEN expression is important, along with other factors, in regulating the acquisition and the maintenance of cytolytic effector function during NK cell maturation. Our data from this study suggest one way it does that is to prevent the proper organization of the cytolytic apparatus. This may be especially relevant in the microenvironment of secondary lymphoid tissue, in which .90% of NK cells are of the CD56 bright NK cell subset, and these cells sit within the parafollicular T cell-rich region of the tissue in direct contact with T cells and dendritic cells that produce several NK activating cytokines including IL-2, IL-12, IL-15, and IL-18 (42, 46) . Other phosphatases that inhibit the PI3K/AKT pathway are expressed at lower levels in the CD56 bright NK cell subset compared with the cytolytic CD56 dim NK cell subset (47) . Thus, abundant PTEN expression in the CD56 bright NK cell subset may be especially important to immune homeostasis.
Our data describe a model in which elevations in PTEN expression decrease the NK cell's ability to attack tumor targets. It is conceivable that variations in PTEN expression within seemingly healthy individuals' NK cells could alter one's ability to effectively inhibit viral infection and/or malignant transformation. Indeed, an 11-y follow-up population study of 3625 people $40 y of age demonstrated that the potency of NK cells in peripheral blood to lyse tumor cell targets is inversely associated with cancer risk (48) . Further, delayed acquisition of NK cell cytolytic function following cancer therapy may contribute to recurrent disease (49) . Perhaps most intriguing is recent evidence that PTEN can be secreted in exosomes and that the exported PTEN retains its lipid phosphatase ability upon entering the recipient cell (50) . This raises the possibility that PTEN could traffic from the tumor cell target, possibly at the immune synapse, thereby immediately inhibiting NK cell activity. A similar mechanism could be potentially applied to other phosphatases with known NK cell function, including SHIP-1. Indeed, a published report has shown the presence of SHIP-1 mRNA within the exosomes of acute myeloid leukemia cell lines and primary acute myeloid leukemia patient samples (51) . Whether at the mRNA or protein level, export of such molecules may offer a duel immune evasion strategy in which tumors can increase proliferation while inhibiting immune effector cell cytolytic activity. Finally, recent evidence indicates that circulating specific exogenous miRs, which are also packaged in exosomes, can modify NK cell function (52) , and several miRs including miR-21, miR-26a, miR-214, miR-221, and miR-222 have each been shown to negatively regulate PTEN (36, (53) (54) (55) (56) . This creates several potential therapeutic targets for enhancing NK cell function that warrant further investigation.
Collectively, our findings demonstrate that the tumor suppressor PTEN can regulate NK cell cytolytic activity. PTEN is expressed at higher levels in the human CD56 bright NK cell subset compared with CD56 dim NK cells, and at high expression levels, PTEN negatively regulates NK cell cytolytic activity against a sensitive leukemia cell target. We then show that loss of PTEN in the CD56 bright NK cell subset increases cytolytic activity. Further, mechanistically, we show that PTEN overexpression disrupts cytolytic activity through inhibition of the organization of the NK cell immune synapse, indicating that PTEN is likely an important regulator of NK cell cytolytic activity.
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